Abstract: Objective:To analyze the different prognoses of the histological subtypes of breast cancer in patients with brain me -tastases. Methods:A total of 89breast cancer patients with brain metastasis were divided into four biological subgroups: the luminal A group ( ER+ and/or PR+, HER-2- ), 17cases; the luminal B group ( ER+ and/or PR+, HER- 2 + ), 15cases; the HER- 2 + group ( EP-,PR-, HER-2 + ), 24cases; and the basal-like group (EP-, PR-, HER-2- ), 33cases. The distribution of the major proportion, age of onset, menstrual status, pathological type, tumor grade, tumor size, lymph node status, and time between operation and brain metastasis were observed. A t-test was used to analyze the data statistically, as well as with an ANOVA. The Kaplan –Meier method and the log-rank test were used to calculate and compare the survival rate through SPSS 15.0. Results: The distribution of patients with basal-like, HER-2 +, luminal A, and luminal B breast cancer with brain metastases was as follows: 37.1%,27%,19.1%, and 16.9%, respectively. Differences in pathological grade were observed, especially in the basal-like group; the percentage of patients in the pathological grade III level was 73% . The basal-like group patients had the worst prognosis. Metastasis was analyzed, which indicated that the lumi-nal-type group patients have higher risk for bone metastasis. In all patients, the median survival time was 47months, the median dis-ease-free survival was20months, and the median survival from brain metastasis was9 months. We found that ER- and PR-, HER2-, and basal-like were each significantly associated with poor survival after diagnosis of brain metastasis. Median survival in the ER- and PR- and ER/PR+ groups were 45and 52months, respectively ( P = 0.006 ). HER-2 + patients, compared with HER-2- patients, had a poor prognosis, (median survival: 45months vs.51.5 months;P = 0.047 ). The patients with the basal-like subtype had the worst prog -nosis of any subtype (median survival time: 33months vs.52months) ( P = 0.000 ). Conclusion:Biological subtype is a useful prog-nostic marker for predicting survival in metastatic breast cancer patients. Patients with brain metastases have poor prognosis when they are of the ER- and PR-, HER- 2+, and basal-like subtypes.